NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ATHA

Athira Pharma Inc

Jul 02 • 04:00PM ET

0.3011

Dollar change +0.0011
Percentage change 0.37	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

| Held by: SURI VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	13.71%	Shs Outstand	39.04M	Perf Week	-3.49%
Market Cap	11.75M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-2.05%	Shs Float	33.69M	Perf Month	5.61%
Enterprise Value	-23.80M	PEG	-	EPS next Q	-0.18	Inst Own	45.08%	Short Float	4.41%	Perf Quarter	11.52%
Income	-79.75M	P/S	-	EPS this Y	75.66%	Inst Trans	14.32%	Short Ratio	2.62	Perf Half Y	-45.24%
Sales	0.00M	P/B	0.31	EPS next Y	29.35%	ROA	-90.12%	Short Interest	1.48M	Perf YTD	-48.68%
Book/sh	0.96	P/C	0.32	EPS next 5Y	62.77%	ROE	-110.70%	52W High	3.67 -91.80%	Perf Year	-88.64%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	-19.25% -73.94%	ROIC	-209.74%	52W Low	0.22 37.14%	Perf 3Y	-89.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.45% 9.09%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	32.23%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.17	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.26	EPS Q/Q	65.92%	SMA20	-4.47%	Beta	2.99	Target Price	0.40
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	2.64%	Rel Volume	0.25	Prev Close	0.30
Employees	26	LT Debt/Eq	0.02	Earnings	May 09 AMC	SMA200	-30.24%	Avg Volume	566.80K	Price	0.30
IPO	Sep 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.17% -	Trades		Volume	139,544	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
04:50AM	Loading…
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
04:05PM	Loading…
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +5.00%
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)
Aug-03-22 11:28AM	Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Aug-02-22 03:30PM	Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-25-22 07:00AM	Athira Pharma to Present Clinical and Preclinical Data at Alzheimers Association International Conference 2022 (GlobeNewswire)
Jul-08-22 04:19PM	Rapid Micro and Athira Pharma Stock See Action From Activist Investors (Barrons.com) -11.44%

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jun 30 '25	Option Exercise	0.00	36,666	0	177,427	Jul 02 04:35 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jul 01 '25	Sale	0.29	8,526	2,502	168,901	Jul 02 04:35 PM
Litton Mark James	President and CEO	Jun 30 '25	Option Exercise	0.00	108,334	0	350,925	Jul 02 04:34 PM
Litton Mark James	President and CEO	Jul 01 '25	Sale	0.29	25,123	7,374	325,802	Jul 02 04:34 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jun 30 '25	Option Exercise	0.00	46,666	0	82,507	Jul 02 04:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	0.29	10,842	3,182	71,665	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jun 30 '25	Option Exercise	0.00	36,666	0	120,401	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jul 01 '25	Sale	0.29	8,526	2,502	111,875	Jul 02 04:33 PM
Renninger Robert	SVP, Finance and Accounting	Jun 30 '25	Option Exercise	0.00	12,359	0	112,083	Jul 02 04:32 PM
Renninger Robert	SVP, Finance and Accounting	Jul 01 '25	Sale	0.29	2,897	850	109,186	Jul 02 04:32 PM
Mark James Litton	Officer	Jul 01 '25	Proposed Sale	0.29	25,123	7,374		Jul 01 07:37 PM
Javier San Martin	Officer	Jul 01 '25	Proposed Sale	0.29	10,842	3,182		Jul 01 07:36 PM
Kevin Church	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:34 PM
Mark Worthington	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM
Mark James Litton	Officer	Sep 05 '24	Proposed Sale	0.00	5,032	1		Sep 05 07:53 PM
Gengos Andrew	CFO and Chief Business Officer	Sep 05 '24	Sale	0.57	1,272	720	97,532	Sep 05 07:51 PM
Lenington Rachel	COO and CDO	Sep 05 '24	Sale	0.57	2,525	1,429	20,870	Sep 05 07:50 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Sep 05 '24	Sale	0.57	2,525	1,429	92,684	Sep 05 07:49 PM
Worthington Mark	GENERAL COUNSEL	Sep 05 '24	Sale	0.57	2,525	1,429	51,927	Sep 05 07:48 PM
Litton Mark James	President and CEO	Sep 05 '24	Sale	0.57	5,032	2,848	159,365	Sep 05 07:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience